BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35914285)

  • 1. Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases.
    de Queiroz Tavares Ferreira F; Araújo DC; de Albuquerque LM; Bianchini PM; Holanda EC; Pugliesi A
    Ocul Immunol Inflamm; 2023 Aug; 31(6):1134-1140. PubMed ID: 35914285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral Panuveitis Mimicking Vogt-Koyanagi-Harada Disease following the First Dose of ChAdOx1 nCoV-19 Vaccine.
    Kim SY; Kang MS; Kwon HJ
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1218-1221. PubMed ID: 35113750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.
    Zou H; Zhang K; Chen X; Sha S
    Immun Inflamm Dis; 2024 Apr; 12(4):e1250. PubMed ID: 38661242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: Bilateral panuveitis resembling Vogt-Koyanagi-Harada disease after second dose of BNT162b2 mRNA COVID-19 vaccine.
    Sato T; Nihei R; Sora D; Nishio Y; Takeuchi M
    Front Immunol; 2022; 13():967972. PubMed ID: 36248859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.
    Rujkorakarn P; Patamatamkul S
    J Fr Ophtalmol; 2023 Mar; 46(3):207-210. PubMed ID: 36775731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
    Joo CW; Kim YK; Park SP
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1250-1254. PubMed ID: 35404752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
    De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A COVID-19 perspective of Vogt-Koyanagi-Harada disease.
    Dutta Majumder P; Sadhu S; González-López JJ; Mochizuki M
    Indian J Ophthalmol; 2023 Jun; 71(6):2587-2591. PubMed ID: 37322685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Developed During Systemic Steroid Therapy for Vogt-Koyanagi-Harada Disease: A Case Report.
    Niidome S; Usui Y; Tsubota K; Sugawara R; Goto H
    Ocul Immunol Inflamm; 2023 Aug; 31(6):1305-1309. PubMed ID: 37084286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine.
    Koong LR; Chee WK; Toh ZH; Ng XL; Agrawal R; Ho SL
    Ocul Immunol Inflamm; 2021 Aug; 29(6):1212-1215. PubMed ID: 34505819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vogt-Koyanagi-Harada Disease and COVID.
    Manni P; Saturno MC; Accorinti M
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.
    Xu K; Gao B; Li J; Xiang Y; Cao L; Zhao M
    Hum Vaccin Immunother; 2023 Aug; 19(2):2220630. PubMed ID: 37282614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
    Accorinti M; Saturno MC; Manni P
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series.
    Pillar S; Weinberg T; Amer R
    Int Ophthalmol; 2023 May; 43(5):1677-1686. PubMed ID: 36316618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harada-like syndrome post-Covishield vaccination: A rare adverse effect.
    Reddy Y; Pandey A; Ojha A; Ramchandani S
    Indian J Ophthalmol; 2022 Jan; 70(1):321-323. PubMed ID: 34937269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vogt-koyanagi-harada syndrome.
    Fang W; Yang P
    Curr Eye Res; 2008 Jul; 33(7):517-23. PubMed ID: 18600484
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Brunet de Courssou JB; Tisseyre M; Hadjadj J; Chouchana L; Broca F; Terrier B; Duraffour P; Henriquez S
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1292-1295. PubMed ID: 35113742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan.
    Herbort CP; Mochizuki M
    Int Ophthalmol; 2007; 27(2-3):67-79. PubMed ID: 17468832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
    Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
    Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine.
    Saraceno JJF; Souza GM; Dos Santos Finamor LP; Nascimento HM; Belfort R
    Int J Retina Vitreous; 2021 Aug; 7(1):49. PubMed ID: 34462013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.